MET and neoplasm: The antibody used in TR1801‐ADC is a nonagonistic binder that enhances the safety of our ADC by reducing downstream signaling of cMet (PI3K/AKT, ERK/MAPK and SRC/focal adhesion kinase pathways) and potential activation of tumor‐promoting events (Greenall et al., 2012; Organ and Tsao, 2011).